MFSD6 and ovarian cancer: Under the condition of progression-free survival (PFS) probability, we found that FBXL7 and MFSD6 transcripts at high levels—but DGKH at low levels—significantly (p < 0.05) predicted a poor prognosis in the unclassified ovarian cancer patients (Figure 3A).